GoodRx Holdings financials
$3.23−2.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $796.9M | $792.3M | $750.3M | $766.6M | $745.4M | $550.7M |
| Gross profit | $739.3M | $744.1M | $683.3M | $701.5M | $698.7M | $521.1M |
| Gross margin | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% |
| Operating income | $87.5M | $65.8M | -$27.0M | $1.7M | $13.4M | -$275.7M |
| Net income | $30.4M | $16.4M | -$8.9M | -$32.8M | -$25.3M | -$293.6M |
| Net margin | 3.8% | 2.1% | −1.2% | −4.3% | −3.4% | −53.3% |
| Diluted EPS | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 |
| EBITDA | $172.7M | $135.4M | $80.7M | $55.9M | $47.9M | -$257.3M |
| Operating cash flow | $167.9M | $183.9M | $138.3M | $128.7M | $178.8M | $131.3M |
| Free cash flow | $93.9M | $113.5M | $82.5M | $73.5M | $144.3M | $95.5M |
| Diluted shares | 357.0M | 392.2M | 410.3M | 412.9M | 410.0M | 274.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $261.8M | $448.3M | $672.3M | $757.2M | $941.1M | $968.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $488.3M | $491.7M | $656.5M | $658.8M | $662.9M | $666.9M |
| Total assets | $1.40B | $1.39B | $1.59B | $1.60B | $1.61B | $1.47B |
| Total liabilities | $787.8M | $663.4M | $826.8M | $789.8M | $775.9M | $758.8M |
| Shareholders' equity | $616.3M | $724.7M | $762.0M | $814.8M | $831.7M | $711.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology